| Trial registration number
|
NCT04756271 |
Full text link
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT04756271
|
First author
Last imported at : Feb. 11, 2022, 3:30 p.m.
Source : ClinicalTrials.gov
|
Noha M Hammad
|
Contact
Last imported at : Feb. 11, 2022, 3:30 p.m.
Source : ClinicalTrials.gov
|
daaboelelaa@medicine.zu.edu.eg
|
Registration date
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
2021-02-16
|
Recruitment status
Last imported at : Feb. 11, 2022, 3:30 p.m.
Source : ClinicalTrials.gov
|
Completed
|
Study design
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
nonRCT
|
Allocation
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Non-randomized
|
Design
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Single group assignment
|
Masking
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Open label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
single-center
|
Study aim
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Prevention
|
Inclusion criteria
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
-healthy healthcare workers
|
Exclusion criteria
Last imported at : Feb. 23, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
- healthy healthcare workers' refusal.
- pregnancy and lactation.
- confirmed acute cases of sars-cov-2 infection
- having a history of sars-cov-2 infection in the past 3 months.
- fever (body temperature > 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose,
pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14
days before vaccination.
- history of allergy to any vaccines
- previous vaccination within the last 30 days
|
Number of arms
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
1
|
Funding
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Zagazig University
|
Inclusion age min
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
18
|
Inclusion age max
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
100
|
Countries
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Egypt
|
Type of patients
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Health workers
|
Severity scale
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
N/A
|
Total sample size
Last imported at : Feb. 11, 2022, 3:30 p.m.
Source : ClinicalTrials.gov
|
246
|
primary outcome
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
Incidence of adverse reactions;Seroconversion rate of neutralizing antibody
|
Notes
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : Feb. 25, 2021, 7:58 p.m.
Source : ClinicalTrials.gov
|
Phase 3
|
Arms
Last imported at : Feb. 18, 2021, 12:31 a.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "2;day0-21", "treatment_id": 1168, "treatment_name": "Sars-cov-2 vaccine (inactivated)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}]
|